



Washington State Health Care Authority
Prescription Drug Program

626 8th Ave SE, Olympia, WA 98501

<https://www.hca.wa.gov/about-hca/prescription-drug-program>

May 30, 2025

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective July 1, 2025:

Newer Anticoagulant Drugs Reviewed 2/28/2024		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
apixaban	Eliquis® tablet	Not participating	Yes
	Eliquis Starter Pack® tablet		Yes
dabigatran etexilate mesylate	dabigatran etexilate capsule		Yes
rivaroxaban	rivaroxaban tablet		Yes
	Xarelto® tablet		Yes
	Xarelto® suspension reconstituted		Yes
	Xarelto Starter Pack® tablet		Yes
The effect of this recommendation is to make rivaroxaban preferred on the WA PDL, and Pradaxa® non-preferred on the WA PDL.			

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our [website](#).

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (360) 725-1188 or by email at leta.evaskus@hca.wa.gov.

Sincerely,

Donna Sullivan
Chief Pharmacy Officer
Clinical Quality and Care Transformation
Washington State Health Care Authority